VERTEX PHARMACEUTICALS INC / MA Research and Development in Process
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Research and Development in Process of $347.10 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-05-02
- VERTEX PHARMACEUTICALS INC / MA research and development in process for the quarter ending 2023-03-31 was $347.10M, a 17255.00% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for the quarter ending 2022-12-31 was $22.60M, a 82.13% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for the quarter ending 2022-09-30 was $29.00M, a 8.61% increase year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for the quarter ending 2022-06-30 was $61.90M, a 93.54% decline year-over-year.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for fiscal 2022 was $115.50M, a 89.63% decline from fiscal 2021.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for fiscal 2021 was $1.11B, a 503.09% increase from fiscal 2020.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for fiscal 2020 was $184.60M.
- VERTEX PHARMACEUTICALS INC / MA research and development in process for fiscal 2019 was $0.00.
| Period end | Research and Development in Process 3 month | Research and Development in Process 6 month | Research and Development in Process 9 month | Research and Development in Process 12 month |
|---|---|---|---|---|
| 2023-03-31 | $347.10M 10-Q · filed 2023-05-02 | $369.70M derived: sum of 2 quarters · filed 2023-05-02 | $398.70M derived: sum of 3 quarters · filed 2023-05-02 | $460.60M derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-12-31 | $22.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $51.60M derived: sum of 2 quarters · filed 2023-02-10 | $113.50M derived: sum of 3 quarters · filed 2023-02-10 | $115.50M 10-K · filed 2023-02-10 |
| 2022-09-30 | $29.00M 10-Q · filed 2022-10-28 | $90.90M derived: sum of 2 quarters · filed 2022-10-28 | $92.90M 10-Q · filed 2022-10-28 | $219.40M derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-06-30 | $61.90M 10-Q · filed 2022-08-05 | $63.90M 10-Q · filed 2022-08-05 | $190.40M derived: sum of 3 quarters · filed 2023-05-02 | $217.10M derived: sum of 4 quarters · filed 2023-05-02 |
| 2022-03-31 | $2.00M 10-Q · filed 2023-05-02 | $128.50M derived: sum of 2 quarters · filed 2023-05-02 | $155.20M derived: sum of 3 quarters · filed 2023-05-02 | $1.11B derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $126.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $153.20M derived: sum of 2 quarters · filed 2023-02-10 | $1.11B derived: sum of 3 quarters · filed 2023-02-10 | $1.11B 10-K · filed 2023-02-10 |
| 2021-09-30 | $26.70M 10-Q · filed 2022-10-28 | $985.10M derived: sum of 2 quarters · filed 2022-10-28 | $986.80M 10-Q · filed 2022-10-28 | |
| 2021-06-30 | $958.40M 10-Q · filed 2022-08-05 | $960.10M 10-Q · filed 2022-08-05 | ||
| 2020-12-31 | $184.60M 10-K · filed 2023-02-10 | |||
| 2019-12-31 | $0.00 10-K · filed 2020-02-13 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $0.00 10-K · filed 2020-02-13 | ||
| 2018-09-30 | $0.00 10-Q · filed 2018-10-25 | |||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $160.00M 10-K · filed 2020-02-13 | ||
| 2017-09-30 | $160.00M 10-Q · filed 2018-10-25 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-13 | $0.00 10-K · filed 2019-02-13 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-10-30 | |||
| 2015-12-31 | $0.00 10-K · filed 2018-02-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |